Ads
related to: androgen prohormone drugs for men 50 and 65 yrs older male with prostate cancer- PTEN Biomarker Results
Information On PTEN Deficiency
Status Can Be A Prognostic Tool.
- PTEN’s Role In mCSPC
Find Out More Information About The
Impact Of PTEN Deficiency In mCSPC.
- PTEN’s Role In mHSPC
Find Out More Information About The
Impact Of PTEN Deficiency In mHSPC.
- Exploring PTEN Incidence
Learn How PTEN Results Provide Info
On Prostate Cancer Approaches.
- PTEN Biomarker Results
Search results
Results From The WOW.Com Content Network
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Antiandrogens are used in the treatment of an assortment of androgen-dependent conditions in both males and females. [4] [9] They are used to treat men with prostate cancer, benign prostatic hyperplasia, pattern hair loss, hypersexuality, paraphilias, and priapism, as well as boys with precocious puberty.
Antiandrogens are medications such as flutamide, nilutamide, bicalutamide, enzalutamide, apalutamide, and cyproterone acetate that directly block the actions of testosterone and DHT within prostate cancer cells. In men with metastatic, hormone-sensitive prostate cancer, doctors may recommend adding taxane-based chemotherapy to hormone therapy. [45]
[78] [79] [80] Of the SAAs, CPA is the only one that has been widely used in the treatment of prostate cancer. [28]: 488 As antiandrogens, the SAAs have largely been replaced by the NSAAs and are now rarely used in the treatment of prostate cancer, due to the superior selectivity, efficacy, and tolerability profiles of NSAAs.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
[13] [102] In men with early prostate cancer, bicalutamide monotherapy has been found to increase non-prostate cancer mortality. [26] [124] [13] The reasons for the increase in mortality with bicalutamide in these men are unknown, but possible factors could include androgen deprivation or drug-related toxicity of bicalutamide. [125] [126]
Ads
related to: androgen prohormone drugs for men 50 and 65 yrs older male with prostate cancer